An outbreak of unexplained illness among heroin users was reported in May 2000 in Dublin. Between 29 April and 26 June 2000, 22 cases were identified, with eight deaths. This occurred in association with similar outbreaks in the UK, particularly Glasgow. Illness was characterised by soft tissue inflammation at the injection site, followed by hypotension and circulatory collapse. Laboratory results indicated that clostridium species were associated with the outbreaks.

Analysis of cases in the UK indicated increased risk for female injectors and longer term users. However, data on injecting practice were unavailable. Injecting intramuscularly has been associated with outbreaks of wound botulism and tetanus. A prospective case-control study was initiated to identify risk factors associated with this outbreak.

## PARTICIPANTS, METHODS, AND RESULTS

Interviews were conducted with case patients who met the international case definition. Surrogates were used for deceased cases and were defined as people who acknowledged routinely injecting drugs in the company of, having a sexual relationship with, or being a close partner or family member of the case patient. Three surrogates were sought for each case. A composite surrogate interview, extracted from the interviews obtained for each case, was used in the final analysis. Interviews with cases or surrogates were obtained from 19 of 22 cases. Two cases were untraceable and in one case all surrogates refused.

At the time of the outbreak, after much publicity, injecting drug users not in treatment came forward for emergency treatment. Sixty five controls were chosen from this group. Controls were therefore injecting drug users from the Dublin area who had injected since 1 April 2000, and who had presented for emergency treatment after publicity about the outbreak. Exclusion criteria included hospitalisation for an abscess or a new local inflammation during the previous two months. Written consent was obtained for participation in the study, and participants were paid £10.

A questionnaire, developed in Glasgow and modified for use in Dublin, was administered by an interviewer. Questions were asked about: demographics, drug use, routes of injection, preparation of drugs to inject, sharing practices, sources of heroin and cocaine, illness, and blood borne virus status. Data were analysed using EpiInfo 6 and Jump In.

On univariate analysis, age group over 30 years, injecting for more than five years, injecting four or more times per day, injecting heroin of a lighter colour, injecting more than 1.0 g per hit, and injecting into muscle were associated with illness (OR > 2). On multivariate analysis, only injecting heroin into muscle remained as being independently associated with illness (table 1).

## COMMENT

Injecting into muscle is usually done when venous access is difficult because of scarring of veins from repeated use. This is consistent with our finding that cases were older and had been injecting for longer lengths of time than controls.

Recommendations are difficult to make as injecting drug use exposes the drug user to many perils. The injecting of heroin or other drugs into muscle may expose users, particularly older and longer term users, to dangers from infections that thrive in an anaerobic environment. Needle exchange programmes to prevent transmission of blood borne virus among injectors may limit infection from shared use of injecting equipment, but these measures may not be effective against spores contained in the drug.

This outbreak brought many drug users forward for treatment. The awareness among drug users of the need to

### Table 1  Drug use and practices of Dublin cases of unexplained illness, compared with controls

<table>
<thead>
<tr>
<th></th>
<th>Case group (n=19)</th>
<th>Control group (n=65)</th>
<th>Odds ratio 95% CI</th>
<th>Adjusted odds ratio 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female sex</td>
<td>6/19 (32)</td>
<td>17/65 (26)</td>
<td>1.30</td>
<td>0.37 to 4.54</td>
</tr>
<tr>
<td>Age group 30+</td>
<td>9/19 (47)</td>
<td>16/65 (25)</td>
<td>2.76</td>
<td>0.94 to 8.08</td>
</tr>
<tr>
<td>Length of time injecting ≥5 yrs</td>
<td>16/19 (84)</td>
<td>43/65 (66)</td>
<td>2.72</td>
<td>0.80 to 12.62</td>
</tr>
<tr>
<td>Blood borne viral status† (HIV/HBV/HCV)</td>
<td>11/19 (58)</td>
<td>26/65 (40)</td>
<td>1.26</td>
<td>0.44 to 3.56</td>
</tr>
<tr>
<td>Injecting heroin into vein</td>
<td>12/19 (63)</td>
<td>62/65 (95)</td>
<td>0.08</td>
<td>0.02 to 0.34</td>
</tr>
<tr>
<td>Injecting heroin into muscle</td>
<td>17/19 (89)</td>
<td>55/65 (85)</td>
<td>28.33</td>
<td>7.09 to 192.2*</td>
</tr>
<tr>
<td>Injecting &gt;4 times/day</td>
<td>10/17 (59)</td>
<td>20/61 (33)</td>
<td>2.93</td>
<td>0.98 to 9.18</td>
</tr>
<tr>
<td>Injecting cocaine</td>
<td>5/19 (26)</td>
<td>19/65 (29)</td>
<td>0.86</td>
<td>0.25 to 2.62</td>
</tr>
<tr>
<td>Polydrug use (heroin +)</td>
<td>6/19 (32)</td>
<td>24/47 (51)</td>
<td>0.44</td>
<td>0.14 to 1.32</td>
</tr>
<tr>
<td>Needle sharing</td>
<td>7/17 (41)</td>
<td>26/64 (41)</td>
<td>1.02</td>
<td>0.33 to 3.01</td>
</tr>
<tr>
<td>Sharing paraphernalia</td>
<td>16/18 (89)</td>
<td>59/65 (91)</td>
<td>0.81</td>
<td>0.17 to 5.91</td>
</tr>
<tr>
<td>Injecting heroin of lighter colour</td>
<td>15/16 (94)</td>
<td>49/64 (77)</td>
<td>4.59</td>
<td>0.82 to 86.4</td>
</tr>
<tr>
<td>Injecting heroin of darker colour</td>
<td>14/18 (78)</td>
<td>45/64 (70)</td>
<td>1.47</td>
<td>0.46 to 5.73</td>
</tr>
<tr>
<td>Injecting &lt;0.5 g</td>
<td>2/13 (15)</td>
<td>23/60 (38)</td>
<td>0.29</td>
<td>0.04 to 1.22</td>
</tr>
<tr>
<td>Injecting 0.5–1.0 g</td>
<td>9/13 (69)</td>
<td>37/60 (62)</td>
<td>1.40</td>
<td>0.40 to 5.64</td>
</tr>
<tr>
<td>Injecting &gt;1.0 g</td>
<td>3/13 (23)</td>
<td>5/60 (8)</td>
<td>3.30</td>
<td>0.60 to 15.81</td>
</tr>
</tbody>
</table>

*p Value < 0.05; † reported positive status for one or more.
treat abscesses and severe tissue inflammation was raised. The critical factor in relation to the response to this outbreak was the multiagency working as demonstrated by regular meeting between the disciplines involved. Thus the accident and emergency services, the Infectious Disease Services, the Drugs Services, and the Public Health Service met on a weekly basis to respond to the crisis. Expanded availability of local treatment services and the quick response of both accident and emergency and drug treatment services to any additional outbreaks will minimise death and illness in this population.

ACKNOWLEDGEMENTS
Outreach staff who conducted interviews: James Fletcher, Joe Merry, Loretta Ratcliffe, Clodagh Rooney. Colleagues in the Scottish Centre for Infection and Environmental Health, Greater Glasgow Health Board and the Centers for Disease Control and Prevention.

Authors’ affiliations
L Mullen, J Barry, M Ward, Department of Public Health, Eastern Regional Health Authority, Dublin, Ireland
D Igoe, National Disease Surveillance Centre, Dublin, Ireland

E Keenan, Drugs Service, South Western Area Health Board, Dublin, Ireland
K Murray, Centers for Disease Control and Prevention, Atlanta, Georgia, USA

Correspondence to: Ms L Mullen; louise.mullen@erha.ie
Accepted for publication 5 February 2002

REFERENCES
Unexplained illness among injecting drug users in Dublin: a case-control study

L Mullen, J Barry, D Igoe, E Keenan, M Ward and K Murray

*J Epidemiol Community Health* 2002 56: 575-576
doi: 10.1136/jech.56.8.575

Updated information and services can be found at: [http://jech.bmj.com/content/56/8/575](http://jech.bmj.com/content/56/8/575)

These include:

**References**
This article cites 5 articles, 1 of which you can access for free at: [http://jech.bmj.com/content/56/8/575#BIBL](http://jech.bmj.com/content/56/8/575#BIBL)

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**
Articles on similar topics can be found in the following collections

- Case-control studies (176)
- Epidemiologic studies (2838)
- Health education (1537)
- Health promotion (1711)
- Occupational and environmental medicine (86)

**Notes**

To request permissions go to: [http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to: [http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to: [http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)